Chardan Capital restated their buy rating on shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) in a research report report published on Wednesday. Chardan Capital currently has a $10.00 price target on the stock.
Separately, Guggenheim reiterated a buy rating and set a $12.00 target price on shares of Aralez Pharmaceuticals in a research report on Thursday, September 15th.
Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 4.80 on Wednesday. Aralez Pharmaceuticals has a 1-year low of $3.10 and a 1-year high of $8.59. The firm’s 50-day moving average is $5.26 and its 200-day moving average is $4.22. The company’s market cap is $313.16 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The business had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $9.70 million. The company’s revenue for the quarter was up 142.3% on a year-over-year basis. On average, equities analysts forecast that Aralez Pharmaceuticals will post ($1.06) earnings per share for the current fiscal year.
In other news, Director Robert Paul Harris sold 150,000 shares of the stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total transaction of $873,000.00. Following the transaction, the director now owns 669,094 shares in the company, valued at approximately $3,894,127.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.77% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. JW Asset Management LLC increased its position in Aralez Pharmaceuticals by 49.1% in the second quarter. JW Asset Management LLC now owns 2,737,140 shares of the company’s stock valued at $9,033,000 after buying an additional 900,765 shares in the last quarter. Deerfield Management Co. bought a new stake in shares of Aralez Pharmaceuticals during the first quarter worth about $5,838,000. Janus Capital Management LLC increased its stake in shares of Aralez Pharmaceuticals by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,603,757 shares of the company’s stock worth $5,292,000 after buying an additional 20,623 shares during the period. Elk Creek Partners LLC increased its stake in shares of Aralez Pharmaceuticals by 8.8% in the second quarter. Elk Creek Partners LLC now owns 1,514,918 shares of the company’s stock worth $2,518,000 after buying an additional 122,172 shares during the period. Finally, Tiger Legatus Capital Management LLC increased its stake in shares of Aralez Pharmaceuticals by 17.6% in the second quarter. Tiger Legatus Capital Management LLC now owns 1,500,000 shares of the company’s stock worth $4,950,000 after buying an additional 225,000 shares during the period. Hedge funds and other institutional investors own 49.65% of the company’s stock.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.